EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers

Zi-Xin Wang, Ju-Hang Chu, Ya-Ru Wang, Lu-Yao Huang, Ming-Ping Qian

Oncology Reviews · 22.04.2026 · 20

DOI: 10.3389/or.2026.1802090 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Reviews, online erschienen am 22.04.2026. Verfasst von Zi-Xin Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC), an aggressive subtype lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, accounts for 10–20% of breast cancers and is characterized by high metastatic potential and poor survival outcomes. Despite advancements in chemotherapy, the 5-year survival rate for metastatic TNBC remains below 30%, underscoring the need for innovative therapeutic approaches. This review comprehensively examines recent breakthroughs in TNBC immunotherapy, focusing on immune checkpoint inhibitors (ICIs), combination strategies, and biomarker-driven therapy. Landmark trials such as KEYNOTE-355 and IMpassion130 have demonstrated that combining PD-1/PD-L1 inhibitors with chemotherapy improves survival in PD-L1-positive metastatic TNBC. Beyond monotherapy, combination therapies—including dual checkpoint inhibition, PARP inhibitors in BRCA-mutated tumors, and antibody-drug conjugates (ADCs) —show promise in overcoming resistance and enhancing antitumor immunity. Emerging targets further expand therapeutic possibilities, though their paradoxical roles as biomarkers and immunosuppressive mediators require precision-based approaches. Biomarkers like PD-L1, tumor-infiltrating lymphocytes (TILs), tumor mutational burden (TMB), and circulating tumor DNA (ctDNA) are critical for patient stratification and predicting immunotherapy response. Despite progress, challenges persist, including tumor heterogeneity, resistance mechanisms, and access to advanced therapies. Future directions emphasize next-generation ICIs, optimized combination regimens, and AI-driven biomarker integration to achieve durable, personalized treatments. This review underscores the potential of immunotherapy to redefine TNBC management while highlighting the imperative for continued innovation to address unmet clinical needs.

Schlagwörter

Stichwörter der Autor:innen

biomarker-driven therapycombination therapyimmune checkpoint inhibitorsimmunotherapytriple-negative breast cancer

Autor:innen und Institutionen

  • Department of General Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Yinshan Lake Hospital of Suzhou Wuzhong District, Jiangsu, China.
  • Department of General Surgery, Shanghai Tenth People's Hospital Chongming Branch, Shanghai, China.

Zitieren

APA

Wang, Z. X., Chu, J. H., Wang, Y. R., Huang, L. Y., & Qian, M. P. (2026). Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers. Oncology Reviews, 20. https://doi.org/10.3389/or.2026.1802090

Vancouver

Wang ZX, Chu JH, Wang YR, Huang LY, Qian MP. Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers. Oncology Reviews. 2026;20. doi:10.3389/or.2026.1802090

BibTeX
@article{Wang2026,
  author = {Wang, Zi-Xin and Chu, Ju-Hang and Wang, Ya-Ru and Huang, Lu-Yao and Qian, Ming-Ping},
  title = {Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers},
  journal = {Oncology Reviews},
  year = {2026},
  volume = {20},
  doi = {10.3389/or.2026.1802090}
}
Kostenlos starten →